Clinical Trials Logo

Plague clinical trials

View clinical trials related to Plague.

Filter by:

NCT ID: NCT00246467 Completed - Plague Clinical Trials

One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

Start date: October 2005
Phase: Phase 1
Study type: Interventional

One hundred and five subjects will be recruited into three groups. Each subject will receive two doses of recombinant plague vaccine at one of three dose levels (rF1 and rV recombinant antigen proteins).

NCT ID: NCT00128466 Completed - Plague Clinical Trials

Treatment and Diagnosis of Plague

Start date: August 2004
Phase: Phase 2/Phase 3
Study type: Interventional

This clinical trial will compare the effectiveness of streptomycin, which historically is the standard drug for treatment of plague, with gentamicin. The hypothesis is that gentamicin is not inferior to streptomycin but that it will have less severe side effects. The study is being done in Madagascar because that country reports the most plague cases in the world. Patients coming into a participating clinic with suspected plague (bubonic, pneumonic, or septicemic) will be randomized into one of two treatment arms after giving informed consent. Patients will be monitored for side effects and for improvement of symptoms. In addition, rapid diagnostic test strips have been developed but not fully evaluated for use on humans. The investigators will evaluate these new tests on specimens from the same patients, comparing their performance with that of classical diagnostic methods such as culture and serology.

NCT ID: NCT00097396 Completed - Preventive Therapy Clinical Trials

Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

Start date: November 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of a two-dose schedule of the recombinant plague vaccine rF1V in healthy volunteers when given as an intramuscular (IM) injection at four ascending dose-levels. The purpose of the Cohort 4 Extension is to evaluate the safety and tolerability of a third intramuscular (IM) dose of 160 ug rF1V in healthy volunteers who have previously been vaccinated with the same concentration of rF1V vaccine.